Genentech's first scientist now focused on Bay Area's latest biotech IPO
October 01, 2018 at 17:30 PM EDT
Dave Goeddel helped build Genentech and Tularik and played a key role in building NGM's portfolio of drugs, including an experimental treatment for nonalcoholic steatohepatitis, or NASH.
